Lepu Med Trials - LARVOL Sigma

63 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Puyouheng (pucotenlimab) / Taizhou Hanzhong Biopharma, Lepu Med

ChiCTR2400085958: A multicenter, prospective clinical study of neoadjuvant CAPOX combined with bevacizumab and pucotenlimab (HX008) in high-risk patients with resectable colorectal liver metastases

Not yet recruiting

100

CAPOX+PD-1+Bevacizumab

The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, SinoCellTech Co., Ltd

high-risk patients with resectable colorectal liver metastases

NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting

560

RoW

Irinotecan Hydrochloride Injection, HX008, Placebo

Taizhou Hanzhong biomedical co. LTD

Stomach Cancer

08/23

NCT05647954: A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver

Not yet recruiting

350

RoW

HX008 + TACE, Temozolomide + TACE, Pembrolizumab

Taizhou Hanzhong biomedical co. LTD

Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms

12/24

06/25

Magic-C002, NCT06976190: A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Not yet recruiting

446

RoW

MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine

Shanghai Miracogen Inc.

Recurrent or Metastatic Nasopharyngeal Carcinoma

05/29

12/30

NCT05652894: A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Not yet recruiting

190

RoW

HX008, Investigator's Choice Chemotherapy

Taizhou Hanzhong biomedical co. LTD

Metastatic Colorectal Cancer

01/26

10/28

NCT04750083: HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Recruiting

2/3

700

RoW

HX008, Pembrolizumab, pemetrexed, cisplatin/carboplatin

Taizhou Hanzhong biomedical co. LTD

Nonsquamous Non-small Cell Lung Cancer

09/22

09/23

NCT03704246: Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Active, not recruiting

123

RoW

Anti-PD-1 monoclonal antibody, HX008

Taizhou Hanzhong biomedical co. LTD

Advanced Solid Tumor

12/19

03/21

HX008-II-MM-01, NCT04749485: A Study of HX008 for the Treatment of Patients With Malignant Melanoma

Active, not recruiting

119

RoW

HX008

Taizhou Hanzhong biomedical co. LTD

Melanoma

08/20

11/21

NCT04741165: Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Recruiting

RoW

HX008, Bevacizumab, AVASTIN®, Lenvatinib, LENVIMA®

Taizhou Hanzhong biomedical co. LTD

Hepatocellular Carcinoma

04/22

10/22

NCT04574817: Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)

Not yet recruiting

RoW

HX008

Taizhou Hanzhong biomedical co. LTD

Anaplastic Thyroid Cancer

05/22

05/23

CHANGEABLE, NCT04508803: Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer

Completed

RoW

HX008，Niraparib, HX008，Niraparib，Trastuzumab, HX008，Niraparib，Pyrrolitinib

Fudan University

Treatment Efficacy

08/22

02/23

NCT04738630: Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Recruiting

110

RoW

HX008

Taizhou Hanzhong biomedical co. LTD

Bladder Cancer

12/22

12/23

NCT06129955: Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma

Not yet recruiting

RoW

Pucotenlimab Combined With Lenvatinib

Sun Yat-sen University

Renal Cell Carcinoma

12/25

CCGLC-012, NCT06192784: Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting

RoW

DEB-TACE, drug eluting beads-transcatheter arterial chemoembolization, Lenvatinib plus pucotenlimab, levima plus pucotenlimab

Tongji Hospital, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer (CCGLC)

Cholangiocarcinoma Non-resectable

01/25

06/25

CCGLC-013, NCT06192797: Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting

RoW

HAIC, hepatic arterial infusion chemotherapy of GEMOX, Lenvatinib plus pucotenlimab, levima plus pucotenlimab

Tongji Hospital, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer

Cholangiocarcinoma Non-resectable

12/26

06/28

NCT06524466: Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma

Active, not recruiting

RoW

Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab

Sun Yat-sen University

Resectable Hepatocellular Carcinoma, Macrovascular Invasion, CNLC IIIA Stage

12/26

NCT06530914: A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma

Not yet recruiting

MRG003 combined with Pucotenlimab, MRG003+Pucotenlimab, MRG003 combined with Pucotenlimab+Cisplatin, MRG003+Pucotenlimab+Cisplatin

Lei Liu

Head and Neck Squamous Cell Carcinoma (HNSCC)

12/26

12/27

NCT06561308: Clinical Efficacy Study of Pucotenlimab Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

Not yet recruiting

RoW

Pucotenlimab, Carboplatin, Paclitaxel, Surgery

Women's Hospital School Of Medicine Zhejiang University, Xiangya Hospital of Central South University, Tongji Hospital, Qilu Hospital of Shandong University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Henan Provincial People's Hospital, Hunan Cancer Hospital, Zhejiang Cancer Hospital, First Affiliated Hospital of Wenzhou Medical University, Ningbo No. 1 Hospital, The First Affiliated Hospital of Zhengzhou University

Endometrioid Endometrial Cancer

09/29

12/29

PUCRT, NCT06770270: Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance

Not yet recruiting

Pucotenlimab

Second Affiliated Hospital, School of Medicine, Zhejiang University

Rectal Cancer

12/27

06/30

NCT06869174: Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary

Not yet recruiting

RoW

Pucotenlimab combined with MRG002

Zhiguo Luo, MD, PhD

Cancer of Unknown Primary

03/27

08/28

SCRIPBOT, NCT06872606: Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer

Not yet recruiting

RoW

Pucotenlimab, Bevacizumab, Oxaliplatin, Trifluridine/Tipiracil Hydrochloride, Short-course radiotherapy, intracavitary brachytherapy

Sir Run Run Shaw Hospital

Rectal Adenocarcinoma

04/26

04/28

NCT06895369: The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC

Not yet recruiting

RoW

Pucotenlimab, Cisplatin, Docetaxel

Sir Run Run Shaw Hospital

Squamous Cell Carcinoma of Head and Neck

12/28

12/33

NCT06969534: Safety and Efficacy of Pucotenlimab in pLECC

Recruiting

RoW

Pucotenlimab combined with GP regimen

Sun Yat-sen University

Lymphoepithelioma-like Carcinoma, Lymphoepithelioma, Carcinoma

12/27

12/28

IDEAL, NCT06959108: Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

Not yet recruiting

106

Pucotenlimab, MRG003

Groupe Oncologie Radiotherapie Tete et Cou, Lepu Medical Technology (Beijing) Co., Ltd.

Locally Advanced Head and Neck Squamous Cell Carcinoma

06/29

10/29

ChiCTR2400091168: A prospective, single-arm, single-center clinical study of neoadjuvant doxorubicin liposome combined with pucotenlimab in the treatment of undifferentiated pleomorphic sarcoma and myxofibrosarcoma

Not yet recruiting

Preoperative treatment: Doxorubicin liposomes, 50mg/m2, intravenously, once every 3 weeks. On the basis of the above chemotherapy regimen, Ptrelizumab was added to the treatment regimen: 200mg intravenously, once every 3 weeks. Postoperative treatment: Relevant examinations were performed 14-21 days after surgery, and postoperative treatment was started after treatment contraindications were excluded. Postoperative chemotherapy was determined by the principal investigator according to the guidelines. In combination with one year of immunomaintenance therapy, the time of treatment initiation was calculated from the first dose of ptolizumab.

Shanghai Changzheng hospital; Shanghai Changzheng hospital

Undifferentiated pleomorphic sarcoma and myxofibrosarcoma

NCT04750382: A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer

Active, not recruiting

1/2

RoW

HX008+Cisplatin+Gemcitabine

Taizhou Hanzhong biomedical co. LTD

Triple-negative Breast Cancer

12/20

12/21

NCT03866525: OH2 Oncolytic Viral Therapy in Solid Tumors

Recruiting

1/2

300

RoW

OH2 injection, with or without irinotecan or HX008

Binhui Biopharmaceutical Co., Ltd.

Solid Tumor, Gastrointestinal Cancer

08/25

NCT04616443: OH2 Injection in Combination With HX008 for Melanoma.

Recruiting

1/2

RoW

OH2 injection, HX008 injection

Binhui Biopharmaceutical Co., Ltd.

Melanoma

11/23

NCT05338957: A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Recruiting

1/2

RoW

MRG002+HX008

Shanghai Miracogen Inc.

Advanced Malignant Solid Tumors

06/24

12/24

NCT06456892: Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen

Recruiting

1/2

RoW

Pucotenlimab

Sun Yat-sen University

Rhabdomyosarcoma, Pediatric Cancer

06/26

12/26

MRG003-C001, NCT05688605: A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Recruiting

1/2

RoW

MRG003+HX008

Shanghai Miracogen Inc.

Advanced Solid Tumors

05/25

07/25

NCT04825392: A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors

Recruiting

RoW

HX008

Taizhou Hanzhong biomedical co. LTD

Advanced Solid Tumor

05/21

12/21

NCT04756934: A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

Recruiting

RoW

HX008, LP002

Taizhou HoudeAoke Biomedical Co., Ltd.

Melanoma

08/21

08/22

NCT05068453: Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis

Not yet recruiting

Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF), OH2, Recombinant humanized anti-PD-1 monoclonal antibody for injection, HX-008, RT, SBRT(stereotactic body radiotherapy)

Beijing Cancer Hospital

Melanoma Stage IV

10/23

12/23

NCT05070221: Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis

Not yet recruiting

Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF), OH2, Recombinant humanized anti-PD-1 monoclonal antibody for injection, HX-008, Axitinib, Inlyta®

Beijing Cancer Hospital

Melanoma Stage IV

10/23

12/23

trastuzumab vedotin (MRG002) / Lepu Med

MRG002-010, NCT05754853: A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Recruiting

290

RoW

MRG002, Docetaxel Injection, Paclitaxel Injection, Gemcitabine Hydrochloride for Injection, Pemetrexed Disodium Injection

Shanghai Miracogen Inc.

Advanced or Metastatic Urothelium Cancer

10/25

01/27

MRG002-004, NCT04924699: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting

2/3

350

RoW

MRG002, Trastuzumab Emtansine for Injection

Shanghai Miracogen Inc.

Advanced Breast Cancer, Metastatic Breast Cancer

09/23

10/23

MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma

06/22

09/22

MRG002-002, NCT04837508: A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced or Metastatic Biliary Tract Cancer

12/22

08/23

Magic-009, NCT05263869: A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Breast Cancer With Liver Metastases

12/22

10/23

MRG002-005, NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced or Metastatic Breast Cancer

02/23

MRG002-008, NCT05141786: A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Not yet recruiting

100

RoW

MRG002

Shanghai Miracogen Inc.

Non-small- Cell Lung Cancer (NSCLC)

12/23

MRG002-007, NCT05141747: A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Locally Advanced Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer

12/23

MRG002-101, NCT04492488: A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Active, not recruiting

1/2

129

MRG002

Shanghai Miracogen Inc.

Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer

10/22

12/24

MRG002-001, NCT04941339: A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced Solid Tumor

10/22

ChiCTR2400086422: MRG 002 for her2 positive advanced paget’s disease: a phase II trial.

Not yet recruiting

MRG 002

FUDAN UNIVERSITY SHANGHAI CANCER CENTER; fudan university shanghai cancer center, lepu pharmacy

paget's disease

LP002 / Lepu Med

NCT04740021: Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

Recruiting

RoW

LP002, Carboplatin, Etoposide

Taizhou HoudeAoke Biomedical Co., Ltd.

Small-cell Lung Cancer

02/22

08/22

NCT04600947: Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Not yet recruiting

RoW

LP002

Taizhou HoudeAoke Biomedical Co., Ltd.

Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

05/22

05/23

NCT04755543: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms

Recruiting

RoW

LP002, Cisplatin, Fluorouracil, OH2 oncolytic virus

Taizhou HoudeAoke Biomedical Co., Ltd.

Digestive System Neoplasms

06/21

06/22

MRG004A / Lepu Med

MRG004A-001, NCT04843709: A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

Recruiting

1/2

181

US, RoW

MRG004A

Shanghai Miracogen Inc.

Advanced or Metastatic Solid Tumors

04/24

06/25

becotatug vedotin (MRG003) / Lepu Med

MRG003-010, NCT05751512: A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Not yet recruiting

180

RoW

MRG003, Cetuximab injection, Methotrexate Injection

Shanghai Miracogen Inc.

Squamous Cell Carcinoma of the Head and Neck

08/25

12/25

ChiCTR2000039157: A Study to evaluate the efficacy and safety of MRG003 in Patients with EGFR-Positive Advanced non-small cell lung cancer

Recruiting

On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.5 mg/kg calculated based on the actual body weight (BW)

Cancer Hospital, Chinese Academy of Medical Sciences; Level of the institution：, Self-financing

EGFR-positive advanced non-small cell lung cancer (NSCLC)

NCT04838548: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Recruiting

RoW

MRG003

Shanghai Miracogen Inc.

Carcinoma, Non-Small-Cell Lung

12/22

02/23

NCT04868162: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recruiting

120

RoW

MRG003

Shanghai Miracogen Inc.

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

01/23

09/23

NCT05188209: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Recruiting

RoW

MRG003

Shanghai Miracogen Inc.

Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Carcinoma

03/23

08/23

MA-HNC-II-006, NCT06509997: A Phase II Study of Anti-EGFR Antibody-drug Conjugate (ADC) Combine With CDK4/6 Inhibitors Posterior Line in the Treatment of Recurrent/Metastatic CDKN2A Gene Variant Head and Neck Squamous Cell Carcinoma

Not yet recruiting

MRG003 combined with Dalpicicilip

Lei Liu

Head and Neck Squamous Cell Carcinoma

12/26

12/27

NCT04838964: A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Recruiting

RoW

MRG003

Shanghai Miracogen Inc.

Advanced or Metastatic Biliary Tract Cancer

10/24

11/24

NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recruiting

238

RoW

MRG003, Capecitabine tablets, Docetaxel injection

Shanghai Miracogen Inc.

Recurrent or Metastatic Nasopharyngeal Carcinoma

10/24

02/25

MRG001 / Lepu Med

NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Recruiting

108

RoW

MRG001

Shanghai Miracogen Inc.

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

10/22

10/23

sonesitatug vedotin (AZD0901) / AstraZeneca

CLARITY-Gastric 01, NCT06346392: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Recruiting

572

Europe, Canada, Japan, US, RoW

AZD0901, Sonesitatug Vedotin, Ramucirumab+ paclitaxel, Paclitaxel, Docetaxel, Irinotecan, TAS-102, Apatinib

AstraZeneca

Gastric Cancer, Gastroesophageal Junction Cancer

04/26

10/26

CLARITY-PanTumor01, NCT06219941: AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Recruiting

190

Europe, Canada, Japan, US, RoW

AZD0901, CMG901, 5-Fluorouracil, 5-FU, Leucovorin, LV, l-leucovorin, I-LV, Irinotecan, Camptosar, Nanoliposomal Irinotecan, ONIVYDE, Gemcitabine, Gemzar

AstraZeneca

Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

12/25

12/26

GEMINI-Gastric, NCT05702229 / 2022-002840-29: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting

240

Europe, Japan, US, RoW

Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD7789, AZD0901, 5-Fluorouracil, Capecitabine

AstraZeneca, AstraZeneca AB

Gastric Cancer

07/26

07/27

KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Completed

176

RoW

CMG901

Keymed Biosciences Co.Ltd

Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer

04/24

BCG006 / Biocytogen, Lepu Med

No trials found

LP010 / Lepu Med

No trials found

LP007 / Lepu Med

No trials found

CTM033 / Lepu Med

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Puyouheng (pucotenlimab) / Taizhou Hanzhong Biopharma, Lepu Med

ChiCTR2400085958: A multicenter, prospective clinical study of neoadjuvant CAPOX combined with bevacizumab and pucotenlimab (HX008) in high-risk patients with resectable colorectal liver metastases

Not yet recruiting

100

CAPOX+PD-1+Bevacizumab

The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, SinoCellTech Co., Ltd

high-risk patients with resectable colorectal liver metastases

NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting

560

RoW

Irinotecan Hydrochloride Injection, HX008, Placebo

Taizhou Hanzhong biomedical co. LTD

Stomach Cancer

08/23

NCT05647954: A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver

Not yet recruiting

350

RoW

HX008 + TACE, Temozolomide + TACE, Pembrolizumab

Taizhou Hanzhong biomedical co. LTD

Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms

12/24

06/25

Magic-C002, NCT06976190: A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Not yet recruiting

446

RoW

MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine

Shanghai Miracogen Inc.

Recurrent or Metastatic Nasopharyngeal Carcinoma

05/29

12/30

NCT05652894: A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Not yet recruiting

190

RoW

HX008, Investigator's Choice Chemotherapy

Taizhou Hanzhong biomedical co. LTD

Metastatic Colorectal Cancer

01/26

10/28

NCT04750083: HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Recruiting

2/3

700

RoW

HX008, Pembrolizumab, pemetrexed, cisplatin/carboplatin

Taizhou Hanzhong biomedical co. LTD

Nonsquamous Non-small Cell Lung Cancer

09/22

09/23

NCT03704246: Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Active, not recruiting

123

RoW

Anti-PD-1 monoclonal antibody, HX008

Taizhou Hanzhong biomedical co. LTD

Advanced Solid Tumor

12/19

03/21

HX008-II-MM-01, NCT04749485: A Study of HX008 for the Treatment of Patients With Malignant Melanoma

Active, not recruiting

119

RoW

HX008

Taizhou Hanzhong biomedical co. LTD

Melanoma

08/20

11/21

NCT04741165: Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Recruiting

RoW

HX008, Bevacizumab, AVASTIN®, Lenvatinib, LENVIMA®

Taizhou Hanzhong biomedical co. LTD

Hepatocellular Carcinoma

04/22

10/22

NCT04574817: Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)

Not yet recruiting

RoW

HX008

Taizhou Hanzhong biomedical co. LTD

Anaplastic Thyroid Cancer

05/22

05/23

CHANGEABLE, NCT04508803: Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer

Completed

RoW

HX008，Niraparib, HX008，Niraparib，Trastuzumab, HX008，Niraparib，Pyrrolitinib

Fudan University

Treatment Efficacy

08/22

02/23

NCT04738630: Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Recruiting

110

RoW

HX008

Taizhou Hanzhong biomedical co. LTD

Bladder Cancer

12/22

12/23

NCT06129955: Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma

Not yet recruiting

RoW

Pucotenlimab Combined With Lenvatinib

Sun Yat-sen University

Renal Cell Carcinoma

12/25

CCGLC-012, NCT06192784: Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting

RoW

DEB-TACE, drug eluting beads-transcatheter arterial chemoembolization, Lenvatinib plus pucotenlimab, levima plus pucotenlimab

Tongji Hospital, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer (CCGLC)

Cholangiocarcinoma Non-resectable

01/25

06/25

CCGLC-013, NCT06192797: Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting

RoW

HAIC, hepatic arterial infusion chemotherapy of GEMOX, Lenvatinib plus pucotenlimab, levima plus pucotenlimab

Tongji Hospital, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer

Cholangiocarcinoma Non-resectable

12/26

06/28

NCT06524466: Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma

Active, not recruiting

RoW

Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab

Sun Yat-sen University

Resectable Hepatocellular Carcinoma, Macrovascular Invasion, CNLC IIIA Stage

12/26

Not yet recruiting

MRG003 combined with Pucotenlimab, MRG003+Pucotenlimab, MRG003 combined with Pucotenlimab+Cisplatin, MRG003+Pucotenlimab+Cisplatin

Lei Liu

Head and Neck Squamous Cell Carcinoma (HNSCC)

12/26

12/27

NCT06561308: Clinical Efficacy Study of Pucotenlimab Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

Not yet recruiting

RoW

Pucotenlimab, Carboplatin, Paclitaxel, Surgery

Endometrioid Endometrial Cancer

09/29

12/29

PUCRT, NCT06770270: Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance

Not yet recruiting

Pucotenlimab

Second Affiliated Hospital, School of Medicine, Zhejiang University

Rectal Cancer

12/27

06/30

NCT06869174: Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary

Not yet recruiting

RoW

Pucotenlimab combined with MRG002

Zhiguo Luo, MD, PhD

Cancer of Unknown Primary

03/27

08/28

Not yet recruiting

RoW

Pucotenlimab, Bevacizumab, Oxaliplatin, Trifluridine/Tipiracil Hydrochloride, Short-course radiotherapy, intracavitary brachytherapy

Sir Run Run Shaw Hospital

Rectal Adenocarcinoma

04/26

04/28

NCT06895369: The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC

Not yet recruiting

RoW

Pucotenlimab, Cisplatin, Docetaxel

Sir Run Run Shaw Hospital

Squamous Cell Carcinoma of Head and Neck

12/28

12/33

NCT06969534: Safety and Efficacy of Pucotenlimab in pLECC

Recruiting

RoW

Pucotenlimab combined with GP regimen

Sun Yat-sen University

Lymphoepithelioma-like Carcinoma, Lymphoepithelioma, Carcinoma

12/27

12/28

Not yet recruiting

106

Pucotenlimab, MRG003

Groupe Oncologie Radiotherapie Tete et Cou, Lepu Medical Technology (Beijing) Co., Ltd.

Locally Advanced Head and Neck Squamous Cell Carcinoma

06/29

10/29

Not yet recruiting

Shanghai Changzheng hospital; Shanghai Changzheng hospital

Undifferentiated pleomorphic sarcoma and myxofibrosarcoma

NCT04750382: A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer

Active, not recruiting

1/2

RoW

HX008+Cisplatin+Gemcitabine

Taizhou Hanzhong biomedical co. LTD

Triple-negative Breast Cancer

12/20

12/21

NCT03866525: OH2 Oncolytic Viral Therapy in Solid Tumors

Recruiting

1/2

300

RoW

OH2 injection, with or without irinotecan or HX008

Binhui Biopharmaceutical Co., Ltd.

Solid Tumor, Gastrointestinal Cancer

08/25

NCT04616443: OH2 Injection in Combination With HX008 for Melanoma.

Recruiting

1/2

RoW

OH2 injection, HX008 injection

Binhui Biopharmaceutical Co., Ltd.

Melanoma

11/23

NCT05338957: A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Recruiting

1/2

RoW

MRG002+HX008

Shanghai Miracogen Inc.

Advanced Malignant Solid Tumors

06/24

12/24

NCT06456892: Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen

Recruiting

1/2

RoW

Pucotenlimab

Sun Yat-sen University

Rhabdomyosarcoma, Pediatric Cancer

06/26

12/26

MRG003-C001, NCT05688605: A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Recruiting

1/2

RoW

MRG003+HX008

Shanghai Miracogen Inc.

Advanced Solid Tumors

05/25

07/25

NCT04825392: A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors

Recruiting

RoW

HX008

Taizhou Hanzhong biomedical co. LTD

Advanced Solid Tumor

05/21

12/21

NCT04756934: A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

Recruiting

RoW

HX008, LP002

Taizhou HoudeAoke Biomedical Co., Ltd.

Melanoma

08/21

08/22

NCT05068453: Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis

Not yet recruiting

Beijing Cancer Hospital

Melanoma Stage IV

10/23

12/23

NCT05070221: Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis

Not yet recruiting

Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF), OH2, Recombinant humanized anti-PD-1 monoclonal antibody for injection, HX-008, Axitinib, Inlyta®

Beijing Cancer Hospital

Melanoma Stage IV

10/23

12/23

trastuzumab vedotin (MRG002) / Lepu Med

MRG002-010, NCT05754853: A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Recruiting

290

RoW

MRG002, Docetaxel Injection, Paclitaxel Injection, Gemcitabine Hydrochloride for Injection, Pemetrexed Disodium Injection

Shanghai Miracogen Inc.

Advanced or Metastatic Urothelium Cancer

10/25

01/27

MRG002-004, NCT04924699: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting

2/3

350

RoW

MRG002, Trastuzumab Emtansine for Injection

Shanghai Miracogen Inc.

Advanced Breast Cancer, Metastatic Breast Cancer

09/23

10/23

MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma

06/22

09/22

MRG002-002, NCT04837508: A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced or Metastatic Biliary Tract Cancer

12/22

08/23

Magic-009, NCT05263869: A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Breast Cancer With Liver Metastases

12/22

10/23

MRG002-005, NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced or Metastatic Breast Cancer

02/23

MRG002-008, NCT05141786: A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Not yet recruiting

100

RoW

MRG002

Shanghai Miracogen Inc.

Non-small- Cell Lung Cancer (NSCLC)

12/23

MRG002-007, NCT05141747: A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Locally Advanced Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer

12/23

MRG002-101, NCT04492488: A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Active, not recruiting

1/2

129

MRG002

Shanghai Miracogen Inc.

Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer

10/22

12/24

MRG002-001, NCT04941339: A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Recruiting

RoW

MRG002

Shanghai Miracogen Inc.

Advanced Solid Tumor

10/22

ChiCTR2400086422: MRG 002 for her2 positive advanced paget’s disease: a phase II trial.

Not yet recruiting

MRG 002

FUDAN UNIVERSITY SHANGHAI CANCER CENTER; fudan university shanghai cancer center, lepu pharmacy

paget's disease

LP002 / Lepu Med

NCT04740021: Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

Recruiting

RoW

LP002, Carboplatin, Etoposide

Taizhou HoudeAoke Biomedical Co., Ltd.

Small-cell Lung Cancer

02/22

08/22

NCT04600947: Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Not yet recruiting

RoW

LP002

Taizhou HoudeAoke Biomedical Co., Ltd.

Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

05/22

05/23

NCT04755543: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms

Recruiting

RoW

LP002, Cisplatin, Fluorouracil, OH2 oncolytic virus

Taizhou HoudeAoke Biomedical Co., Ltd.

Digestive System Neoplasms

06/21

06/22

MRG004A / Lepu Med

MRG004A-001, NCT04843709: A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

Recruiting

1/2

181

US, RoW

MRG004A

Shanghai Miracogen Inc.

Advanced or Metastatic Solid Tumors

04/24

06/25

becotatug vedotin (MRG003) / Lepu Med

MRG003-010, NCT05751512: A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Not yet recruiting

180

RoW

MRG003, Cetuximab injection, Methotrexate Injection

Shanghai Miracogen Inc.

Squamous Cell Carcinoma of the Head and Neck

08/25

12/25

ChiCTR2000039157: A Study to evaluate the efficacy and safety of MRG003 in Patients with EGFR-Positive Advanced non-small cell lung cancer

Recruiting

On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.5 mg/kg calculated based on the actual body weight (BW)

Cancer Hospital, Chinese Academy of Medical Sciences; Level of the institution：, Self-financing

EGFR-positive advanced non-small cell lung cancer (NSCLC)

NCT04838548: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Recruiting

RoW

MRG003

Shanghai Miracogen Inc.

Carcinoma, Non-Small-Cell Lung

12/22

02/23

NCT04868162: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recruiting

120

RoW

MRG003

Shanghai Miracogen Inc.

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

01/23

09/23

NCT05188209: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Recruiting

RoW

MRG003

Shanghai Miracogen Inc.

Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Carcinoma

03/23

08/23

Not yet recruiting

MRG003 combined with Dalpicicilip

Lei Liu

Head and Neck Squamous Cell Carcinoma

12/26

12/27

NCT04838964: A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Recruiting

RoW

MRG003

Shanghai Miracogen Inc.

Advanced or Metastatic Biliary Tract Cancer

10/24

11/24

NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recruiting

238

RoW

MRG003, Capecitabine tablets, Docetaxel injection

Shanghai Miracogen Inc.

Recurrent or Metastatic Nasopharyngeal Carcinoma

10/24

02/25

MRG001 / Lepu Med

NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Recruiting

108

RoW

MRG001

Shanghai Miracogen Inc.

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

10/22

10/23

sonesitatug vedotin (AZD0901) / AstraZeneca

Recruiting

572

Europe, Canada, Japan, US, RoW

AZD0901, Sonesitatug Vedotin, Ramucirumab+ paclitaxel, Paclitaxel, Docetaxel, Irinotecan, TAS-102, Apatinib

AstraZeneca

Gastric Cancer, Gastroesophageal Junction Cancer

04/26

10/26

CLARITY-PanTumor01, NCT06219941: AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Recruiting

190

Europe, Canada, Japan, US, RoW

AZD0901, CMG901, 5-Fluorouracil, 5-FU, Leucovorin, LV, l-leucovorin, I-LV, Irinotecan, Camptosar, Nanoliposomal Irinotecan, ONIVYDE, Gemcitabine, Gemzar

AstraZeneca

Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

12/25

12/26

GEMINI-Gastric, NCT05702229 / 2022-002840-29: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting

240

Europe, Japan, US, RoW

Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD7789, AZD0901, 5-Fluorouracil, Capecitabine

AstraZeneca, AstraZeneca AB

Gastric Cancer

07/26

07/27

KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Completed

176

RoW

CMG901

Keymed Biosciences Co.Ltd

Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer

04/24

BCG006 / Biocytogen, Lepu Med

No trials found

LP010 / Lepu Med

No trials found

LP007 / Lepu Med

No trials found

CTM033 / Lepu Med

No trials found

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites